Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia.

Blood Cancer Journal
Ann-Kristin SchmaelterMohamad Mohty

Abstract

Following chemotherapy, secondary acute myeloid leukemia (sAML), occurring after antecedent hematologic diseases, previous chemotherapy or radiation, has an inferior prognosis compared with de novo AML. To define the outcome of sAML in the context of allogeneic stem cell transplantation (alloSCT), a retrospective, registry-based comparison was performed, including 11,439 patients with de novo and 1325 with sAML. Among transplants in first complete remission (CR1) (n = 8,600), the 3-year cumulative incidence of relapse (RI) and non-relapse mortality (NRM) was 28.5% and 16.4% for de novo, and 35% and 23.4% for sAML. Three-year overall survival (OS), leukemia-free survival (LFS) and Graft-versus-Host Disease/relapse-free survival (GRFS) was 60.8%, 55.1%, and 38.6% for de novo, and 46.7%, 41.6%, and 28.4% for sAML, respectively. In multivariate analysis, sAML was associated with a lower OS (HR = 1.33 [95% CI = 1.21-1.48]; p < 10-5), LFS (HR = 1.32 [95% CI = 1.19-1.45]; p < 10-5) and GRFS (HR = 1.2 [95% CI = 1.1-1.31]; p < 10-4) and higher NRM (HR = 1.37 [95% CI = 1.17-1.59]; p < 10-4) and RI (HR = 1.27 [95% CI = 1.12-1.44]; p < 10-3). Results of the Cox model were confirmed in a matched-pair analysis. In contrast, results did not d...Continue Reading

References

Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Aug 21, 2007·Current Oncology Reports·Gautam Borthakur, And Elihu E Estey
Aug 12, 2008·Seminars in Oncology·Lucy A Godley, Richard A Larson
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boglarka GyurkoczaBrenda M Sandmaier
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lene Sofie Granfeldt ØstgårdJan Maxwell Nørgaard
Mar 21, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bartlomiej M GettaMikhail Roshal
Apr 22, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Salyka SengsayadethArnon Nagler
Jul 20, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E LancetBruno C Medeiros

❮ Previous
Next ❯

Citations

Jul 22, 2021·American Journal of Hematology·Juliane GrimmSebastian Schwind
Aug 25, 2021·Transplantation and Cellular Therapy·Leland MethenyMarcos de Lima
Sep 18, 2021·Current Opinion in Hematology·Anne E Austin, Michael Byrne

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Software Mentioned

R
SPSS

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.